Meet with Rob Singer from Rosa & Co. at Biopharm America, Oct 4-5, 2022. https://buff.ly/3V0T5rd. Rob will be speaking with biotech and pharmaceutical companies about Rosa’s ForecastMD™ Platform and to investors about Rosa’s new DueDiligenceMD service. This will be a virtual meeting.
Rosa & Co. is pleased to announce it is offering DueDiligenceMD in addition to the ForecastMD™ Research Platform. For organizations that are evaluating assets for in-licensing, partnering, or acquisition, DueDiligenceMD quantifies and explains the expected physician demand for the asset, based on primary market research and an Excel®-based Revenue Model. DueDiligenceMD projects are typically completed within two weeks.
Rosa & Co. is also enhancing our PhysioPD® Research with the use of Artificial Intelligence/ Machine Learning (AI/ML) techniques. PhysioPD Research provides biological context, facilitates insight into dynamics and causality, and supports hypothesis generation. Adding AI/ML techniques to PhysioPD Research speeds the identification of networks from data, supports empirical model and Virtual Patient creation, and enriches the insights extracted from simulation results.
See the press release at https://www.einnews.com/pr_new...
Rosa & Co. LLC is pleased to announce that Dr. Bill Brastow, Chief Technology Officer for Rosa Market Modeling, will present a webinar "Injecting Reality into Commercial Due Diligence for In-Licensing, Partnering or Purchasing Pharmaceutical Assets in Development" on Wednesday, August 17, 2022, at 12:00 to 1:00 pm EDT.
As part of the Rosa World-Wide Webinar Series, this webinar focuses on how pharmaceutical and biotech companies can inject reality into the commercial opportunity analysis by measuring expected physician demand for the drug to inform revenue projections and decisions about in-licensing, partnering, or purchasing these assets.
To learn more or register for the webinar, see: https://rosaandco.com/webinars
Rosa will be at Oncology Europe 2022 on June 14, 2022. Mike Reed, Chief Scientist, PhysioPD will be presenting. Come meet us live and in person! https://buff.ly/3KgHmir
Rosa & Co is pleased to announce the release of a new video discussing how a ForecastMD™ Market Model can quantify physician demand for a prescription drug or diagnostic test under multiple product profiles or competitive scenarios. The video is part of Rosa’s 20th-anniversary celebration. The video is available at Market Model Implications.
Rosa & Co is pleased to announce the release of a new video discussing how the ForecastMD™ Excel-based Market Model is a durable asset that our clients can use over multiple years to quantify physicians' demand for their prescription drug or diagnostic test as the market changes over time.
The video is part of Rosa’s 20th anniversary celebration. The video is available at Durable Asset.
Come see Rosa at the Oncology Strategy Meeting, San Francisco, May 11, 2022. Live and in person! https://buff.ly/3LIhPyJ
Rosa and Servier will be presenting a talk and a poster on modeling systemic lupus erythematosus next week at Quantitative Systems Pharmacology Conference 2022 (QSPC2022), in Leiden, the Netherlands https://www.qspc.eu/qspc2022. Dr. Christina Friedrich from Rosa will be presenting “Predicted efficacy of a pan neutralizing anti interferon-alpha (IFN-α) monoclonal antibody in a virtual systemic lupus erythematosus (SLE) patient cohort using a mechanistic SLE PhysioPD QSP model” on Friday 4/22. Rosa & Co. is a proud sponsor for this important QSP conference.
Rosa & Co is pleased to announce the release of a new video discussing how our ForecastMD™ Market Model Platform can quantify how a new prescription drug or diagnostic test may take market share from current options.
The video is part of Rosa’s 20th-anniversary celebration. Click to see the ForecastMD™ Platform Dynamics video.
Rosa & Co is pleased to announce the release of a new video discussing how our ForecastMD™ Market Model Platform helps commercial teams from biotechnology, pharmaceutical, and diagnostic companies simulate physician demand for their new product in a variety of competitive scenarios.
The video is part of Rosa’s 20th-anniversary celebration. Click here to see the ForecastMD™ Platform Overview Video.
Rosa & Co is thrilled to announce the release of a video celebrating its 20th-anniversary. The company is celebrating this historic event with videos, events, and news throughout the year. Click here to see our 20th-Anniversary Video.
Rosa & Co is pleased to announce the release of a new white paper “Commercializing Life Science Products. Which Product Properties Are Important in Convincing Physicians and Patients to Use My Product? And How to Ask This Question”. The paper describes a scientific approach to HCP product selection.
Rosa is excited to announce the launch of the ForecastMD™ Platform. Rosa's Life Sciences clients use this proprietary, quantitative market modeling technique to inform product design decisions and commercial viability assessments. See the press release.
Rosa & Co is thrilled to announce its 20th anniversary. The company will be celebrating this historic event with videos, events, and news throughout the year. See the 20th anniversary press release.
Rosa & Co. announced today the publication of an article titled, “Brief Report: Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology Model,” which was published on Research Square on December 22, 2021.
To read the article: https://www.auctoresonline.org...
Rosa & Co. announced today the contributions of Drs. Christina Friedrich, Vincent Hurez, and Maria-Luisa Ruiz to the article titled, “Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3- kinase inhibitors,” which was published in CPT Pharmacometrics Systems Pharmacology on December 1, 2021.
To read the article: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.12749
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.
To read the press release: https://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-updates-comparative-pharmacology-model
Rosa & Co. is proud to announce that a poster authored by Rosa scientists will be presented at the upcoming virtual American Conference on Pharmacometrics (ACoP) meeting.
Christina Friedrich, Ph.D., Chief Engineer at Rosa & Co. and Renee Meyers, Modeling Associate at Rosa & Co., will be presenting a poster titled, “Surrogate Modeling with Machine Learning for Faster Virtual Patient Cohort Generation in QSP Models.” The presentation will take place on Tuesday, November 9th from 8:45 AM to 9:30 AM and 12:45 PM to 1:30 PM EST.
The 2021 ACoP Meeting will take place virtually from November 8-12, 2021.
Rosa & Co. is proud to announce that a poster authored by Rosa scientists will be presented at the upcoming 14th International Congress of Inborn Errors of Metabolism (ICIEM) meeting.
Rebecca Baillie, Ph.D, Principal Scientist and Chief of Staff at Rosa & Co, will be presenting a poster titled, “Using Modeling for Dose Recommendations of A Novel Drug for Urea Cycle Disorders”. The presentation will be a digital poster included within the Congress virtual platform.
The 2021 ICIEM meeting will take place virtually and in person from November 21-23, 2021. https://www.iciem2021.com.au/
Rosa & Co. is proud to announce that two posters authored by Rosa scientists will be presented at the upcoming Population Approach Group in Europe (PAGE) virtual meeting.
Vincent Hurez, DVM, Ph.D, a Senior Scientist at Rosa & Co., will be presenting a poster titled, “Development of a systemic lupus erythematosus (SLE) QSP model linking systemic biomarkers to cutaneous clinical score (CLASI) outcomes”. The presentation will take place at Poster Session II on Monday, September 6, 2021, from 12:00 PM to 1:00 PM CET.
Rebecca Baillie, Ph.D., Principal Scientist and Chief of Staff at Rosa & Co., will be presenting a poster titled, “Reuse of a published model to support compassionate use of novel drug formulation for a rare disorder”. The presentation will take place at Poster Session III on Tuesday, September 7, 2021, from 12:00 PM to 1:00 PM CET.
The 2021 PAGE meeting will take place virtually from September 2-7, 2021.